The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-Mutant Non-Small Cell lung cancer.
Hanxiao ChenDingzhi HuangGen LinXue YangMinglei ZhuoYujia ChiXiaoyu ZhaiBo JiaJingjing WangYuyan WangJianjie LiTongtong AnMeina WuZiping WangJun ZhaoPublished in: Cancer medicine (2022)
KRAS is an important driver gene in NSCLC, compromising 12.1% in this study, and G12C was noted as the most common subtype. Patients with KRAS-mutant NSCLC could benefit from pemetrexed-based chemotherapy and ICIs.